Xvivo Perfusion AB (publ)
XVIPY · OTC
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Market Cap | $8,916,412 | $9,811,869 | $14,902,076 | $15,969,995 |
| - Cash | $322,995 | $315,871 | $415,521 | $449,982 |
| + Debt | $110,808 | $29,308 | $34,043 | $9,835 |
| Enterprise Value | $8,704,225 | $9,525,306 | $14,520,598 | $15,529,848 |
| Revenue | $178,295 | $218,588 | $227,564 | $198,480 |
| % Growth | -18.4% | -3.9% | 14.7% | – |
| Gross Profit | $132,655 | $160,374 | $175,134 | $147,931 |
| % Margin | 74.4% | 73.4% | 77% | 74.5% |
| EBITDA | $16,020 | $37,867 | $28,068 | $20,472 |
| % Margin | 9% | 17.3% | 12.3% | 10.3% |
| Net Income | $1,573 | -$12,399 | $36,387 | $85,817 |
| % Margin | 0.9% | -5.7% | 16% | 43.2% |
| EPS Diluted | 0.013 | -0.098 | 0.29 | 0.68 |
| % Growth | 112.8% | -133.6% | -57.4% | – |
| Operating Cash Flow | $8,798 | -$15,251 | $62,084 | $22,876 |
| Capital Expenditures | -$36,100 | -$18,200 | -$22,231 | $0 |
| Free Cash Flow | -$27,302 | -$33,451 | $39,853 | $22,876 |